The Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models grant opportunity is to support preclinical HIV/AIDS research using NHP models performed by Early Stage Investigators (ESIs) who are within 10 years of their terminal degree or completion of their residency training but who have at least two years of postdoctoral experience.
Donor Name: National Institutes of Health (NIH)
State: All States
County: All Counties
Type of Grant: Grant
Deadline: 04/07/2025
Size of the Grant: $100,000 to $500,000
Grant Duration: 2 Years
Details:
The goal of this support is to help advance HIV/AIDS researchers using NHP models in preclinical research by providing a degree of independence for these ESIs to develop new research directions and to position these researchers to be competitive for new research funding (e.g., R01). Proposed projects must use NHPs as preclinical models for HIV/AIDS research. This funding initiative encompasses all priorities of the fiscal year (FY) 2021-2025 NIH Strategic Plan for HIV and HIV-Related Research reduce the incidence of HIV; develop next-generation HIV therapies; conduct research toward HIV cure; address HIV-associated comorbidities, coinfections, and complications; and advance cross-cutting areas of research.
The topics of interest to this NOFO include, but are not limited to:
- Vaccines, vaccine adjuvants and other novel antiretroviral therapy-free approaches to viral remission or eradication directed towards Simian Immunodeficiency Virus/Simian-Human Immunodeficiency Virus (SIV/SHIV) at various stages of the lifespan, including neonates and infants;
- Non-vaccine prevention, such as oral pre-exposure prophylaxis neutralizing monoclonal antibodies, or mucosal microbicides;
- Antiretrovirals, safe and effective combination antiretroviral treatment (cART), or combined drug/immunotherapeutic approaches;
- Identification, characterization, and therapeutic targeting of anatomic sanctuary sites that serve as latent reservoirs of the virus during antiretroviral treatment (ART);
- Identification of biomarkers for predicting viral remission or reactivation/rebound of latent virus;
- Impact of co-morbidities and co-infections on SIV/SHIV acquisition/transmission, progression to AIDS, and/or interactions with treatment modality; and
- Imaging and monitoring/tracking SIV/SHIV, immune cells, and anti-SIV/SHIV antibodies.
Funding Information
No more than $200,000 in direct costs may be requested in any single year. The combined budget may not exceed $400,000 direct costs for the two-year period.
Project Period
The total project period may not exceed 2 years.
Eligibility Criteria
- Eligible Organizations
- Nonprofits Other Than Institutions of Higher Education
- Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)
- For-Profit Organizations
- Small Businesses
- For-Profit Organizations (Other than Small Businesses)
- Local Governments
- State Governments
- County Governments
- City or Township Governments
- Special District Governments
- Indian/Native American Tribal Governments (Federally Recognized)
- Indian/Native American Tribal Governments (Other than Federally Recognized).
- Federal Governments
- U.S. Territory or Possession.
For more information, visit Grants.gov.
